On Target to Outsmart Cancer August 2025 © 2025 Revolution Medicines, Inc. 2 Legal Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, business strategy, prospective products, availability of funding, ability to manage existing collaborations and establi ...

Q2 Earnings AUGUST 6, 2025 SkyWater Technology Forward-Looking Statements This presentation contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements that are based on the Company's current expectations or forecasts of future events, rather than past events and outcomes, and such statements are not guarantees of future performance. Forward-looking statements include all statements other than statements of historical fact contained ...

Q3 2025 Financial Performance - Net revenue decreased by 13% year-over-year, impacted by the launch of Ace in Q3 2024 and challenging market conditions, offset partially by home theater strength[11] - GAAP gross margin declined by 490 bps year-over-year, primarily due to higher inventory reserves, reorganization efforts, and deleverage[11] - Non-GAAP gross margin decreased by 400 bps year-over-year, for the same reasons as GAAP gross margin[11] - Tariffs reduced Q3 2025 GAAP and Non-GAAP gross margin by 60 bps, equivalent to $2.1 million[11] - Adjusted EBITDA decreased by $13 million year-over-year due to lower revenue and gross profit, partially offset by lower expenses[12] - Free cash flow declined in Q3 2025 due to working capital changes, partially offset by lower capital expenditure and higher cash earnings[14] Inventory and Cash Flow - Inventories decreased by $39 million, a 25% year-over-year reduction, mainly driven by component inventory workdown[17] - Finished goods inventory decreased by $9 million, a 9% year-over-year decrease[17] - Component balance decreased by $30 million, a 58% year-over-year decrease[17] - Cash flow from operations was $37 million, a decrease of $26 million year-over-year from $64 million in Q3 2024[20] - Capital expenditures were $5 million, down $18 million year-over-year due to the launch of Ace in Q3 2024[20] - Free cash flow was $33 million, a decrease of $7 million year-over-year from $40 million in Q3 2024[20] Operating Expenses and Outlook - Non-GAAP Research and Development expenses were $53 million, down 17% year-over-year due to cost optimization efforts[21] - Non-GAAP Sales and Marketing expenses were $58 million, down 13% year-over-year driven by lower marketing investment[21] - Non-GAAP General and Administrative expenses were $20 million, down 16% year-over-year due to cost optimization efforts[21] - Non-GAAP Operating Expenses were $131 million, down 15% year-over-year, with normalized Non-GAAP Operating Expenses down 23% year-over-year[21] - The company expects Q4 2025 revenue to be between $260 million and $290 million, representing a growth of 2% to 14% year-over-year[26]

Second Quarter 2025 Financial Results © 2025 RB Global, Inc. | All Rights Reserved Forward-Looking Statements Forward-Looking Statements: Certain statements contained in this presentation include "forward-looking statements" within the meaning of U.S. federal securities laws and "forward-looking information" within the meaning of Canadian securities laws (collectively, "forward-looking statements"). Forward-looking statements herein include, in particular, statements relating to future financial and operati ...

2Q25 Earnings Presentation August 6, 2025 Published by: Sinclair, Inc. 111 NON-GAAP FINANCIAL MEASURES This presentation contains certain financial measures of Sinclair, Inc. (the "Company"), including Adjusted EBITDA, which are not prepared in accordance with U.S. generally accepted accounting principles ("GAAP") (collectively, the "non-GAAP financial measures"). Adjusted EBITDA is defined as earnings before interest, tax, depreciation and amortization, and non-recurring and unusual transaction, implementa ...

Financial Performance - The company's Annual Recurring Revenue (ARR) reached $502 million, showing a year-over-year growth of 5%[9] - Subscription revenue accounted for 76% of the company's total revenue on a trailing twelve-month (TTM) basis[9] - The company's Non-GAAP gross margin was 73%, and the Non-GAAP operating margin was 19% on a TTM basis[9] - Free cash flow was $146 million, resulting in a free cash flow margin of 19% on a TTM basis[9] - Q1 FY26 revenue was $195 million, an 11% increase year-over-year[12] Revenue Breakdown - Subscription revenue in Q1 FY26 was $148 million, a 10% increase year-over-year[14] - Marketplace & Other revenue in Q1 FY26 was $46 million, a 13% increase year-over-year[14] - US revenue in Q1 FY26 was $184 million, an 11% increase year-over-year[14] - International revenue in Q1 FY26 was $11 million, a 9% increase year-over-year[14] Outlook - The company projects Q2 FY26 revenue to be approximately $197 million, representing a 6% year-over-year growth[25]

1 2 Confidential & Proprietary – Do not distribute. © 2024 Zevia PBC 3 Source: Confidential & Proprietary – Do not distribute. © 2024 Zevia PBC 4 1Numerator Shopper Metrics Report for 12M ending 06/30/2025 which incorporates expanded scope of BFY Soda Brands in 2Q25 4 • • • • • | 2025 | Net Sales | Gross Margin | Net Loss | Adjusted EBITDA¹ | | --- | --- | --- | --- | --- | | 02 | $44.5 million +10.1% vs. PY | 48.7% +680 basis points vs. PY | -$0.7 million +$6.3 million vs. PY | +$0.2 million +$4.6 million ...

Financial Performance - Total revenue reached $54.8 million, a 16% increase compared to the second quarter of 2024[10] - Software revenue grew by 15% to $40.5 million[10] - Drug discovery revenue increased by 19% to $14.2 million[10] - Cash and marketable securities increased by 21% to $462.3 million as of June 30, 2025[28] - Deferred revenue surged by 289% to $186.5 million[28] Guidance and Outlook - The company maintains its software growth and drug discovery revenue guidance[10] - Operating expenses are expected to be lower than in 2024[10] - Third-quarter software revenue is projected to be between $36 million and $40 million[10] - The company anticipates software revenue to increase by 10%–15% in 2025[31] - Drug discovery revenue is projected to be between $45 million and $50 million in 2025[31] Pipeline and Development - Initial Phase 1 data for SGR-1505 was presented in June, with strategic opportunities for clinical development being explored[11] - Initial Phase 1 data for SGR-2921 and SGR-3515 are expected in the fourth quarter of 2025[11]

Financial Performance - Total revenue decreased by 8% year-over-year to $248.2 million in Q2 2025[25] - Bumble App revenue decreased by 8% year-over-year to $201.4 million in Q2 2025[25] - The company reported a net loss of $367 million in Q2 2025[25] - Adjusted EBITDA increased by 26% year-over-year to $94.6 million in Q2 2025, with an Adjusted EBITDA margin of 38.1%[25, 48] User Metrics - Total paying users decreased by 9% year-over-year to 3.8 million in Q2 2025[25] - Bumble App paying users decreased by 11% year-over-year to 2.5 million in Q2 2025[25] - Total Average Revenue per Paying User (ARPPU) increased by 1% year-over-year to $21.69 in Q2 2025[25] - Badoo App and Other paying users decreased by 3% year-over-year[36] Future Outlook - The company expects total revenue of $240-$248 million for Q3 2025[44] - Bumble App revenue is projected to be $194-$200 million for Q3 2025[44] - Adjusted EBITDA is expected to be $79-$84 million for Q3 2025[44]

Q3 FY25 Performance Highlights - The company achieved record Q3 and Year-to-Date GAAP and Non-GAAP EPS [12] - Significant margin expansion was observed during the quarter [12] - There was a major improvement in workplace safety performance [12] Financial Results - Q3 net sales were $960.913 million [49] - GAAP gross margin was 34.6% [49] - Non-GAAP operating income was $139.041 million [49] - Adjusted EBITDA reached $166.568 million [50] Segment Performance - Pet segment net sales were $493 million with a non-GAAP operating margin of 15.8% [28] - Garden segment net sales were $468 million with a non-GAAP operating margin of 18.2%, up 310 bps [29, 30] Outlook - The company reaffirmed fiscal year 2025 non-GAAP EPS guidance of approximately $2.60 [15]